Abstract: The present application discloses a bending-resistant polyester film and its production method thereof. The chemical structure of the bending-resistant polyester composition comprises monomers having elastic conformation. The film made from the composition of polyester of the present invention through production processes such as melt extrusion and biaxial drawing still has excellent flexibility and optical properties.

Abstract: A quantum-dot optical film comprises: a binder, wherein a plurality of quantum dots, and a plurality of clay fragments are dispersed in the binder, wherein each of the clay fragments is capable of being water-resistant and oxygen-resistant.

Abstract: A quantum-dot optical film comprising a quantum-dot layer, a first base film and a first coating layer, wherein the first coating layer is coated on the base film, wherein the first coating layer is disposed on a top surface of the quantum-dot layer, the first coating layer comprising a first polymer and clay fragments dispersed in the first polymer for being water-resistant and oxygen-resistant.

Abstract: The present invention relates to compounds useful for degrading BTK via a ubiquitin proteolytic pathway. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

Abstract: Disclosed are compounds of Formula I: or a pharmaceutically acceptable salt, a solvate, a tautomer, a stereoisomer or a deuterated analog thereof, wherein A1, A2, A3, A4, R4, X1, X2, and X3 are as described in any of the embodiments described in this disclosure; compositions thereof; and uses thereof.

Abstract: An implantable prosthetic valve assembly, according to one embodiment, comprises a frame assembly including a plurality of struts and a prosthetic valve secured inside the frame assembly by sutures. At least one of the plurality of spaced struts contains at least one hole that passes from one side of the at least one strut to another side of the at least one strut and a recess disposed around the hole.

Abstract: Disclosed are compounds of Formula I: or a pharmaceutically acceptable salt, a solvate, a tautomer, a stereoisomer or a deuterated analog thereof, wherein A1, A2, A3, A4, R4, X1, X2, and X3 are as described in any of the embodiments described in this disclosure; compositions thereof, and uses thereof.

Abstract: An implantable prosthetic valve assembly, according to one embodiment, comprises a frame assembly including a plurality of struts and a prosthetic valve secured inside the frame assembly by sutures. The sutures are inward of the outermost surface of an outer periphery of the frame assembly. In certain embodiments the struts contain recesses in which sutures can be disposed. In other embodiments, the struts can have holes through them which the sutures pass through. The implantable prosthetic valve assembly can also be collapsed within a catheter such that an outermost surface of a periphery of the frame assembly touches the catheter but the sutures are spaced apart from the catheter or are flush with the outer surface of the frame.

Abstract: The present invention discloses a quantum-dot film, wherein the quantum-dot film comprises a binder and a plurality of quantum dots dispersed in the binder, wherein the plurality of quantum dots are capable of being water-resistant and oxygen-resistant.

Abstract: The present invention discloses a quantum-dot composite optical film comprising: a plurality of quantum dots dispersed in the optical film, wherein the plurality of quantum dots are capable of being water-resistant and oxygen-resistant; and a plurality of prisms, disposed over the quantum-dot layer.

Abstract: Disclosed are morpholino oligonucleotides that can be used to silence expression of MGMT, pharmaceutical compositions that include said morpholino oligonucleotides, and methods of using said morpholino oligonucleotides in the treatment of cancer, particularly methods that involve the use of radiation to deliver said morpholino oligonucleotides.

Abstract: Disclosed are morpholino oligonucleotides that can be used to silence expression of MGMT, pharmaceutical compositions that include said morpholino oligonucleotides, and methods of using said morpholino oligonucleotides in the treatment of cancer, particularly methods that involve the use of radiation to deliver said morpholino oligonucleotides.

Abstract: Disclosed are compounds of Formula I: or a pharmaceutically acceptable salt, a solvate, a tautomer, an isomer or a deuterated analog thereof, wherein R4, X3, X4, X5, X6, X7 and Ring A are as described in any of the embodiments described in this disclosure; compositions thereof; and uses thereof.

Abstract: Disclosed are morpholino oligonucleotides that can be used to silence expression of MGMT, pharmaceutical compositions that include said morpholino oligonucleotides, and methods of using said morpholino oligonucleotides in the treatment of cancer, particularly methods that involve the use of radiation to deliver said morpholino oligonucleotides.

Abstract: Heterocyclic compounds of formula (I), methods for their preparation, pharmaceutical compositions containing such a compound and their therapeutic uses.

Abstract: A load indicator for use with a fall protection apparatus having a line and a connector for connecting to a user includes a housing having a pass-through opening and a covered indicator region. At least a portion of the housing is configured for connecting to the line. The load indicator also includes a shear pin supported by the housing and extending across the pass-through opening, and a saddle extending across at least a portion of the pass-through opening and supported by at least a portion of the shear pin. The saddle is configured for connecting to at least a portion of the connector. The saddle is movable relative to the housing between a first position and a second position when a force exceeding a predetermined threshold value is applied on the saddle causing the shear pin to shear or break. At least a portion of the indicator region is uncovered in the second position of the saddle when the shear pin shears or breaks.

Abstract: An implantable prosthetic valve assembly, according to one embodiment, comprises a frame assembly including a plurality of struts and a prosthetic valve secured inside the frame assembly by sutures. The sutures are inward of the outermost surface of an outer periphery of the frame assembly. In certain embodiments the struts contain recesses in which sutures can be disposed. In other embodiments, the struts can have holes through them which the sutures pass through. The implantable prosthetic valve assembly can also be collapsed within a catheter such that an outermost surface of a periphery of the frame assembly touches the catheter but the sutures are spaced apart from the catheter or are flush with the outer surface of the frame.

Abstract: A scheduling system and method for data cleansing may be used to optimize clinical scheduling. The present disclosure describes receiving clinical record data, in an agnostic manner, from a system including a source scheduling database containing the clinical record data; mapping the clinical record data to a desired format; conforming the clinical record data to standardized scheduling elements of the scheduling system; cleansing, in a manner configurable by a user, the clinical record data to purge portions of the clinical record data; providing the clinical record data to an optimization engine for optimization of the clinical record data; optimizing the clinical record data by applying configurable logic to the clinical record data; and uploading one or more newly defined optimized scheduling templates via an outbound connection back to the scheduling system.

Abstract: Disclosed are compounds of Formula I(b): or a pharmaceutically acceptable salt, a solvate, a tautomer, an isomer or a deuterated analog thereof, wherein Ring A, Ring HD, J, each T, R3, R4, R5, each R7, and m are as described in any of the embodiments described in this disclosure; compositions thereof; and uses thereof.

Abstract: A scheduling system and method for data cleansing may be used to optimize clinical scheduling. The present disclosure describes receiving clinical record data, in an agnostic manner, from a system including a source scheduling database containing the clinical record data; mapping the clinical record data to a desired format; conforming the clinical record data to standardized scheduling elements of the scheduling system; cleansing, in a manner configurable by a user, the clinical record data to purge portions of the clinical record data; providing the clinical record data to an optimization engine for optimization of the clinical record data; optimizing the clinical record data by applying configurable logic to the clinical record data; and uploading one or more newly defined optimized scheduling templates via an outbound connection back to the scheduling system.